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Abstract
Background: It has been proposed that there are abnormalities in incentive motivational
processing in psychosis, possibly secondary to subcortical dopamine abnormalities, but few
empirical studies have addressed this issue.
Methods: We studied incentive motivation in 18 first-episode psychosis patients from the
Cambridge early psychosis service CAMEO and 19 control participants using the Cued
Reinforcement Reaction Time Task, which measures motivationally driven behaviour. We also
gathered information on participants' attentional, executive and spatial working memory function
in order to determine whether any incentive motivation deficits were secondary to generalised
cognitive impairment.
Results: We demonstrated the anticipated "reinforcement-related speeding" effect in controls (17
out of 19 control participants responded faster during an "odd-one-out" task in response to a cue
that indicated a high likelihood of a large points reward). Only 4 out of 18 patients showed this
effect and there was a significant interaction effect between reinforcement probability and diagnosis
on reaction time (F1,35 = 14.2, p = 0.001). This deficit was present in spite of preserved executive
and attentional function in patients, and persisted even in antipsychotic medication free patients.
Conclusion: There are incentive motivation processing abnormalities in first-episode psychosis;
these may be secondary to dopamine dysfunction and are not attributable to generalised cognitive
impairment.
Background
Motivational problems such as avolition have been noted
in schizophrenia since the initial descriptions of the ill-
ness [1]. Proposed neurological models of psychosis have
linked schizophrenic motivational deficits to hypofron-
tality, but an alternative hypothesis is that motivational
dysfunction in schizophrenia and other psychoses is
underpinned by abnormal activity of subcortical
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monoamine systems [2-4]. In particular, ascending mid-
brain dopamine neurons are known to play a key role in
incentive motivation [5,6] and to signal unexpected
reward and errors in reward prediction [7]. Reward system
dysfunction may underlie not only avolition but also, or
alternatively, other psychotic symptoms including stereo-
typed patterns of thought and behaviour [8] and delu-
sional beliefs [8-13]. For example, it has been argued that
dysregulated midbrain dopamine neuron firing could
result in an individual maladaptively attributing motiva-
tional importance to innocuous stimuli or events, i.e.
experiencing abnormal referential ideas [10,11]. An
affected individual, having experienced abnormally sali-
ent phenomena secondary to dysregulated dopamine,
may then impose a "top-down" cognitive explanation
onto such experiences in order to make sense of them,
potentially culminating in a delusion [10]. Alternatively,
dysregulated dopamine neuron firing could result in an
amplification of the salience of an internally generated
voice, which could in turn lead to an abnormal perception
[14].
In spite of such speculations that disrupted reward and
motivational processing may underpin positive and/or
negative psychotic symptoms, it has yet to be clearly dem-
onstrated whether such disruptions are present in psycho-
sis or not, let alone whether such disruptions relate to
symptom expression. A major challenge in evaluating the
hypothesis that reward processing is abnormal in psycho-
sis is the lack of available behavioural measures to assess
reward processing and incentive motivational processes in
humans; the consequence has been that, to date, such
processes have only been addressed indirectly in behav-
ioural studies. Patients with schizophrenia display a range
of abnormalities of classic associative learning phenom-
ena including Kamin blocking and latent inhibition
[15,16], and these abnormalities are responsive to short-
term antipsychotic treatment, consistent with a dopamin-
ergic mechanism. In addition, reward-based decision-
making on the Iowa Gambling Test (IGT) has been shown
to be impaired in psychosis [17] and these effects are also
sensitive to medication status [18], although there have
been some failures to replicate the case-control difference
[19], and the IGT requires several cognitive processes in
addition to reward sensitivity.
In the present study, we sought to examine incentive
motivation in psychosis, using a simple choice reaction
time task (the Cued Reinforcement Reaction Time Task, or
CRRT [20]) in which healthy participants have previously
shown speeding of responses after presentation of col-
oured cues signalling higher probability of reward: 'rein-
forcement-related speeding'. Thus a particular cue (an
initially and objectively neutral piece of information)
becomes associated with enhanced likelihood of rein-
forcement, and so stimulates more effortful (i.e. rapid)
responding in an adaptive performance of the task. We
administered the CRRT to a group of patients with first-
episode psychosis, in addition to a number of neuropsy-
chological tests of attentional and executive function. By
studying first-episode cases, we were able to explore moti-
vational processes in the absence of substantial global
cognitive impairment. We hypothesised that patients with
psychosis would be less sensitive than healthy partici-
pants to the motivational manipulation, and would there-
fore show attenuated or absent 'reinforcement-related
speeding' on the task.
Methods
Participants
18 individuals (mean age 23; 9 men) with first-episode
psychosis were recruited from the Cambridge first episode
psychosis service, CAMEO for the study. Inclusion criteria
for CAMEO is age between 17 and 35, suffering from a
first episode of psychosis as defined by the Melbourne cri-
teria of the presence of psychotic symptoms for at least
one week [21], and duration of antipsychotic treatment of
under 6 months at the time of initial assessment. Nine-
teen healthy volunteers (mean age 25; 9 men) were
recruited from the general population by advertisement to
act as a control group. Eleven of the 18 patients were tak-
ing antipsychotic medication; all of these 11 were taking
"atypical" antipsychotic agents with a mean chlorpro-
mazine equivalent dose of 264 mg. Of these, 3 were taking
olanzapine (10 mg daily), 2 risperidone (1 mg daily and
3 mg daily), 2 quetiapine (500 mg daily and 400 mg
daily), 1 clozapine (400 mg daily), 2 aripiprazole (10 mg
daily and 15 mg daily), and 1 amisulpride (200 mg daily).
Of the 7 antipsychotic-free patients, 5 were taking no
medication, 1 was taking sertraline and 1 sodium val-
proate. Only 1 of the antipsychotic free patients had pre-
viously briefly taken antipsychotics, but was antipsychotic
free for 2 weeks prior to assessment. After referral to the
service, we waited until clinical presentation at least par-
tially stabilised before commencing the study (over 75%
studied within 5 months of referral, all assessed within a
year of referral). As a consequence most patients in this
study had mild symptoms at the time of the experiment:
mean Brief Psychiatric Rating Scale (BPRS) positive symp-
tom score 1.8 (very mild) and mean BPRS negative symp-
tom score 1.8 (very mild). BPRS scores were unavailable
on two patients. Twelve months after the experiment, a
psychiatrist (GM) assigned DSM-IV diagnoses to patients
using all available clinical information; 9 patients met cri-
teria for schizophrenia, 2 for schizoaffective disorder, 5
for bipolar disorder, 1 for delusional disorder and 1 for
psychosis not otherwise specified. This range of diagnoses
is broadly representative of outcomes in first episode psy-
chosis services [22]. The research was approved by theBMC Psychiatry 2008, 8:34 http://www.biomedcentral.com/1471-244X/8/34
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local Research Ethics Committee; all participants pro-
vided informed consent.
The Cued Reinforcement Reaction Time Task [20]
On each trial, participants perform a rapid 'odd-one-out'
judgment on three shapes, one of which is distinct (Figure
1). Stimuli presentation was preceded by a cue (a col-
oured rectangle of one of 3 colors) that signalled the like-
lihood that a correct response would be followed by a
reward (the three colors were associated with 10, 50, and
90% reinforcement probability). 96 trials were adminis-
tered in the test, with 32 trials of each cue-type. Responses
were made with the dominant hand, and were immedi-
ately followed by feedback: correct identification of the
odd-one-out yielded a green smiley face; incorrect
responses yielded a red sad face. The magnitude of rein-
forcement was dependent on accuracy and reaction time
(RT): a fast correct response was rewarded with 100
points, a slow correct response with 1 point, and an incor-
rect response with 0 points. Participants were told that
they had to obtain as many points as possible and were
subsequently given a debrief questionnaire in order to
provide a measure of explicit awareness of stimulus-rein-
forcement contingencies. RT thresholds were titrated for
each individual participant in a practice session, which
also served to familiarise the participants with the task. In
the practice session, which consisted of two blocks of 20
trials, no cues were presented and no trial by trial feedback
was provided. The mean RT and standard deviation for
the second practice block was used to compute a cut-off
for reward delivery in the main task, so that reward attain-
ment levels were titrated to individual subjects' psycho-
motor speed. The cut-off was calculated by subtracting the
standard deviation from the mean RT.
Additional Neuropsychological Measures
Three further tests (described in Additional file 1: infor-
mation on additional neuropsychological measures) from
the Cambridge Neuropsychological Test Automated Bat-
tery (CANTAB) were administered to assess attentional
and executive function: the Intra-Dimensional/Extra-
Dimensional (ID/ED) Shift test [derived from the Wiscon-
sin Card Sort Test, see 23], the Rapid Visual Information
Processing (RVIP) test [derived from the Continuous Per-
formance Test, see 24], and the Spatial Working Memory
(SWM) test [25].
Data Analysis
Demographic characteristics of the two groups were com-
pared using independent-samples t-tests and chi-squared
tests. Incorrect trials were excluded from the CRRT reac-
tion time analysis. CRRT performance was assessed using
mixed-model ANOVA with group (patients, controls) as a
between-subjects factor, and probability of reinforcement
(10%, 50%, 90%) as a within-subjects factor. A linear con-
trast was used to test for reaction time trend across the
reinforcement contingencies [26,27]. Debriefing data
were analysed with chi-squared tests. In order to attempt
to rule the possibility that differences between groups
were attributable to the effects of dopamine antagonist
medication, we repeated the mixed-model ANOVA hav-
ing excluded the participants who were taking antipsy-
chotic drugs. The proportion of participants in each group
who showed reinforcement-related speeding (responding
faster on trials with a high probability of reinforcement
than on trials with a low probability of reinforcement)
was compared using a Chi-Squared Test when all patients
were included and Fisher's exact test when antipsychotic
treated patients were excluded.
Skewed data were transformed where possible to enable
the use of parametric tests. A logarithmic transformation
was used for ID/ED extra-dimensional shift errors and
total errors, and for RVIP latency data. A square root trans-
formation was used for SWM between errors and within
errors. Fisher's Exact Test was used to compare the number
of participants from each group who completed the ID/
ED test. The Mann Whitney U-Test was used to compare
The CRRT (Cued Reinforcement Reaction Time Task) Figure 1
The CRRT (Cued Reinforcement Reaction Time 
Task). Participants were asked to identify the 'odd-one-out' 
on each trial as fast as possible without making mistakes. A 
coloured stimulus window acted as a cue, indicating the 
probability of receiving reinforcement. Reinforcement was 
100 points and a smiley face for a response faster than the 
cutoff score (top right), 1 point and a smiley face for a 
response slower than the cutoff score (bottom right), and 0 
points and a sad face for an incorrect response (not shown). 
Reinforcement probabilities were 10, 50, and 90% (depend-
ing on the colour of the cue). No feedback was presented 
and no points were obtained on the remaining (unreinforced) 
trials.BMC Psychiatry 2008, 8:34 http://www.biomedcentral.com/1471-244X/8/34
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RVIP response bias data groups. All tests were two-tailed
with alpha set at 0.05.
Results
Cued Reinforcement Reaction Time Task
Whilst 17 of the 19 controls showed reinforcement-
related speeding (faster reaction times on the high proba-
bility trials compared to the low probability trials), only 4
of the 18 patients showed that effect (X2  = 17, p =
0.00004). The degree of the reinforcement-related speed-
ing effect is shown in Figures 2 and 3. Analysis of variance
revealed no main effect of reinforcement probability (F2,70
= 0.6 p = 0.6) or diagnostic group (F1,35 = 0.9, p = 0.3), but
a significant diagnostic group by reinforcement probabil-
ity interaction (F2,70 = 4.5, p = 0.025). The trend of reac-
tion time across reinforcement contingencies differed in
controls compared with patients (F1,35 = 14.2, p = 0.001).
Control participants displayed a significant effect of rein-
forcement probability on reaction in a repeated-measures
ANOVA (F2,17 = 12, p = 0.001), whereas there was no such
effect in the psychosis patients (F2,16 = 0.9, p = 0.4). Anal-
ysis of the error data showed no significant differences
between groups (t = 1.2, p = 0.3). When we excluded the
patients who were taking antipsychotic medication, the
proportion of participants showing reinforcement-related
speeding still differed significantly across groups (Fisher's
exact test p = 0.006) and the effect of differing reaction
time trend across reinforcement probabilities in controls
and in patients remained significant (F1,24 = 4.5, p =
0.045). There was no significant difference between
groups in explicit awareness of reinforcement contingen-
cies (p = 0.89): 58% of controls and 66.6% of patients cor-
rectly identified the colour most likely to lead to a reward.
We also examined whether the mean reaction time from
the second block of practice, and the standard deviation of
reaction times from the second block of practice differed
between groups (as these were used in order to calculate
the cut-off thresholds for the task proper). However, there
was no difference between groups on practice mean RT (t
= 0.3, p = 0.8) or practice RT standard deviation (t = 0.5,
p = 0.6).
We then examined the correlation between symptoms
and reinforcement-related speeding, but there was no sig-
nificant relationship (r = 0.3, p = 0.3, negative symptoms;
r = 0.03, p = 0.9, positive symptoms).
Other cognitive test scores (Table 1)
there were no significant differences between groups on
set-shifting or attentional function. 15 out of 18 patients
passed all stages of the ID/ED Test, compared to 18 out of
19 control volunteers (p = 0.3). There was no significant
difference between groups on number of extra-dimen-
sional shift errors (t = 1.4, p = 0.2), or on pre-extradimen-
sional shift errors (t = 0.4, p = 0.7) or on total errors (t =
1.4, p = 0.2). In the RVIP, there was no difference between
groups in terms of response bias (U = 109, p = 0.2), target
detection (t = 1.6, p = 0.13) or latency (t = 0.5, p = 0.6).
Reaction time stratified by reinforcement probability in the  Cued Reinforcement Reaction Time Task Figure 3
Reaction time stratified by reinforcement probability 
in the Cued Reinforcement Reaction Time Task. This 
plot demonstrates reinforcement-related speeding in con-
trols (as defined by a linear trend of decreasing reaction time 
with increasing probability of reinforcement) and an interac-
tion between reinforcement-related speeding and diagnostic 
group (p = 0.001). Error bars represent standard errors of 
the mean difference in reaction times on the 90% probability 
trials compared with the 10% probability trials.
The degree of reinforcement-related speeding in patients and  controls Figure 2
The degree of reinforcement-related speeding in 
patients and controls. The mean degree of reinforcement-
related speeding (as measured by the mean reaction time on 
90% probability trials minus the mean reaction time on 10% 
probability trials) differs in patients and controls (t = 3.8, p = 
0.001). Error bars represent standard errors of the mean.BMC Psychiatry 2008, 8:34 http://www.biomedcentral.com/1471-244X/8/34
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Patients showed impairment in spatial working memory
on strategy score (t = 2.7, p = 0.01) and on between-stage
errors (t = 2.5, p = 0.02). Spatial working memory scores
were unavailable for 4 control participants due to techni-
cal problems. There was no difference between groups on
the subsidiary measure of within stage-errors (t = 1, p =
0.3).
We then examined the relationship between incentive
motivation and spatial working memory. We performed a
logistic regression analysis in patients to test whether the
presence of reinforcement-related speeding can be pre-
dicted by spatial working memory performance. Neither
spatial working memory strategy score (p = 0.3) nor
between search error score (p = 0.2) predicted the pres-
ence of reinforcement-related speeding. We further exam-
ined whether the degree of reinforcement-related
speeding (mean reaction time on 90% probability of rein-
forcement trials – mean reaction time of 10% probability
trials, and mean RT on 90% probability trials – mean RT
on 50% probability trials) correlated with spatial working
memory performance in patients. These correlations were
not significant: r = 0.35, p = 0.2 (mean RT 90-50 vs strat-
egy); r = 0.02, p = 0.9 (mean RT 90-10 v strategy); r = 0.1,
p = 0.7 (mean RT 90-50 vs between search errors); r = 0.3,
p = 0.2 (mean RT 90-10 vs between search errors).
Finally we tested whether patients who ultimately were
diagnosed with schizophrenia performed differently on
cognitive tests from those ultimately diagnosed with bipo-
lar disorder, but there was no significant difference on any
test.
Discussion
Control participants demonstrated an adaptive behav-
ioural response to cues of varying degree of motivational
salience (acquired through association with reward).
Whilst the majority of patients were able to report cor-
rectly the cue most associated with reward, they did not
show the adaptive behavioural reinforcement-related
speeding effect of controls. As such, there was a disconnec-
tion between their awareness of the environment, and
their ability to modulate their behaviour in accordance
with that knowledge. This supports the theory that
patients with early psychosis show deficits in incentive
motivation.
Whilst we follow other authors in arguing that incentive
motivation plays a key role in response speeds and laten-
cies during reinforcement tasks in general [28,29] and the
CRRT in particular [20,30], we do acknowledge that other
cognitive processes also contribute to the CRRT, including
attentional and learning processes. We note that these
first-episode psychosis patients did form a fairly cognitive
intact group, given their good performance on attentional
set shifting and rapid information processing. The use of
these comparison cognitive assessments shows that the
patients' abnormal performance in the CRRT was not
purely secondary to generalised cognitive deficits and is
likely to truly reflect abnormalities in motivational
processing. Patients did show impaired spatial working
memory, in accordance with previous evidence docu-
menting spatial working deficits early in the course of psy-
chotic illness [31]. However, patients' spatial working
memory deficits did not relate to their performance on the
CRRT, indicating that the incentive motivation abnormal-
ities we observed were not confounded by the patients'
cognitive deficits. We note that there was a moderate, but
non-significant, correlation between spatial working
memory strategy and performance on the CRRT. A recent
study [32] that investigated motivation processing in
chronic medicated schizophrenia also showed a moderate
correlation between motivated responding and working
memory. It is possible that if we had used a larger sample
size we might have seen a significant relationship between
CRRT performance and working memory, and this area
warrants further study in larger samples.
Some limitations should be noted. The sample size is
small, and some of the patients were taking atypical antip-
sychotic medication, which may have affected the results.
However there is evidence that atypical antipsychotic
agents do not impair motivational processing in patients
with psychosis, but rather such medications may amelio-
rate underlying abnormalities in reward expectation in the
ventral striatum [33]. Furthermore, when we excluded
patients who were taking antipsychotic medication from
the analysis, a statistically significant difference between
groups in incentive motivation remained, which suggests
that the abnormality in patients is not solely attributable
to dopamine antagonist effects of treatment.
Table 1: Cognitive Test Scores
Test Control Psychosis p
ID/ED (Proportion completing)* 83% 95% 0.3
ID/ED EDS errors 4.3 (5.9) 7.9 (9.6) 0.2
ID/ED Pre-EDS errors 5.7 (2.2) 6 (2.5) 0.7
ID/ED Total errors 11.3 (6.1) 15.2 (9.8) 0.2
SWM Between Errors 14.3 (13.4) 24.2 (14.4) 0.02
SWM Within Errors 1.1 (1.6) 1.6 (2.1) 0.3
SWM Strategy 26.3 (6.4) 32.3 (6.4) 0.01
RVIP Target Detection 0.94 (0.05) 0.91 (0.05) 0.13
RVIP Response Bias$ 0.96 (0.04) 0.97 (0.05) 0.3
RVIP Latency 409.7 (80.6) 429.7 (118.5) 0.6
Means (Standard Deviation) are shown for the two groups on the 
additional cognitive tests, with p-values for statistical tests for group 
difference t-tests apart from * (Chi-Square) and $(Mann-Whitney U).BMC Psychiatry 2008, 8:34 http://www.biomedcentral.com/1471-244X/8/34
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A variety of evidence from studies in both humans and
experimental animals indicates that subcortical dopamine
systems play a critical role in reward and motivational
processing [34,35]. Dopamine may be more critical in
motivation, anticipation of rewards and prediction error
signalling than in consummatory processing, which has
been linked to opioid receptor activation [7,36]. Despite
extensive previous theorising attempting to link
dopamine dysfunction, abnormalities in reward process-
ing, and psychosis [8,10,14], few experimental behav-
ioural or physiological studies have investigated such
theories in patients. In a recent functional MRI study of
reward learning, Murray et al [37] showed that brain
responses correlating with reward prediction error in the
dopaminergic midbrain and associated dopamine neuron
striatal and limbic target regions were abnormal in
patients with active psychotic symptoms. Juckel and col-
leagues [38] demonstrated that expectation of reward,
when compared with expectation of neutral feedback, is
associated with reduced ventral striatal activity in schizo-
phrenia when compared to controls. Taken together, these
studies provide preliminary evidence for physiological
abnormalities in psychotic illness in learning about and
anticipating rewards, combined with an impaired ability
to modulate behaviour in response to incentives. We sug-
gest that this impairment may be secondary to dopamine
dysfunction, though we acknowledge that, as yet, no
direct evidence has proved that performance on the CRRT
is dopamine dependent. In contrast to demonstrated
anticipatory and motivational deficits, consummatory
reward processing in psychosis may be intact [32,39,40].
Conclusion
This study reports deficits in incentive motivation process-
ing in first episode psychosis. Future studies should exam-
ine whether incentive motivation deficits in psychosis are
sensitive to pharmacological, especially dopaminergic,
modulation.
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